chidamide + CHOP

Chidamide + CHOP is a combination therapy consisting of the histone deacetylase inhibitor chidamide and the standard chemotherapy regimen known as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone). Chidamide is an oral small molecule that selectively inhibits histone deacetylases (HDACs), leading to altered gene expression and apoptosis in malignant cells. The addition of chidamide to the conventional CHOP regimen has been investigated primarily for angioimmunoblastic T-cell lymphoma (AITL) and other peripheral T-cell lymphomas. Clinical studies have shown that this combination can improve overall survival and response rates compared to CHOP alone in newly diagnosed AITL patients[1][3][9]. The mechanism of action involves both epigenetic modulation by chidamide and cytotoxic effects from the chemotherapeutic agents in CHOP.

Other names

chidamide plus CHOPchidamide combined with CHOP